MannKind (MNKD) | Financial Analysis & Statements
MannKind Corporation Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
112.0M
Gross Profit
82.3M
73.50%
Operating Income
-7.7M
-6.87%
Net Income
-15.9M
-14.25%
EPS (Diluted)
$-0.05
Balance Sheet Metrics
Total Assets
792.2M
Total Liabilities
843.2M
Shareholders Equity
-51.0M
Cash Flow Metrics
Operating Cash Flow
-20.3M
Free Cash Flow
-10.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
MannKind Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 349.0M | 285.5M | 199.0M | 99.8M | 75.4M |
| Cost of Goods Sold | 88.0M | 76.6M | 62.8M | 57.5M | 38.9M |
| Gross Profit | 261.0M | 208.9M | 136.2M | 42.3M | 36.6M |
| Gross Margin % | 74.8% | 73.2% | 68.5% | 42.4% | 48.5% |
| Operating Expenses | |||||
| Research & Development | 66.3M | 45.9M | 31.3M | 19.7M | 12.3M |
| Selling, General & Administrative | 144.1M | 94.3M | 94.3M | 91.5M | 77.4M |
| Other Operating Expenses | - | - | - | - | 339.0K |
| Total Operating Expenses | 210.5M | 140.2M | 125.6M | 111.2M | 90.1M |
| Operating Income | 46.6M | 68.7M | 10.6M | -68.9M | -53.5M |
| Operating Margin % | 13.3% | 24.1% | 5.3% | -69.1% | -70.9% |
| Non-Operating Items | |||||
| Interest Income | 8.1M | 12.6M | 6.2M | 2.5M | 112.0K |
| Interest Expense | 37.8M | 38.0M | 25.2M | 24.8M | 16.6M |
| Other Non-Operating Income | -15.2M | -12.8M | -2.0M | 3.8M | -11.0M |
| Pre-tax Income | 1.4M | 30.5M | -10.4M | -87.4M | -80.9M |
| Income Tax | -4.5M | 2.9M | 1.6M | 0 | 0 |
| Effective Tax Rate % | -316.7% | 9.6% | 0.0% | 0.0% | 0.0% |
| Net Income | 5.9M | 27.6M | -11.9M | -87.4M | -80.9M |
| Net Margin % | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% |
| Key Metrics | |||||
| EBITDA | 65.7M | 90.4M | 22.7M | -60.2M | -50.4M |
| EPS (Basic) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
| EPS (Diluted) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
| Basic Shares Outstanding | 305639000 | 274415000 | 267014000 | 257092000 | 249244000 |
| Diluted Shares Outstanding | 305639000 | 274415000 | 267014000 | 257092000 | 249244000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
MannKind Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 74.9M | 46.3M | 238.5M | 69.8M | 124.2M |
| Short-term Investments | 96.5M | 150.9M | 56.6M | 101.1M | 79.9M |
| Accounts Receivable | 38.4M | 11.8M | 14.9M | 16.8M | 4.7M |
| Inventory | 35.3M | 27.9M | 28.5M | 21.8M | 7.2M |
| Other Current Assets | 46.6M | 31.4M | 34.8M | 25.5M | 3.5M |
| Total Current Assets | 291.6M | 268.3M | 373.4M | 234.9M | 219.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 459.9M | 9.1M | 4.9M | 6.0M | 0 |
| Intangible Assets | 324.7M | 5.3M | 1.1M | 1.2M | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 20.9M | 27.5M | 7.4M | 9.7M | 8.4M |
| Total Non-Current Assets | 500.6M | 125.5M | 101.8M | 60.4M | 101.7M |
| Total Assets | 792.2M | 393.8M | 475.2M | 295.3M | 321.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 9.0M | 6.8M | 9.6M | 11.1M | 7.0M |
| Short-term Debt | 38.4M | - | 20.0M | 9.6M | 7.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 51.3M | 27.1M | 28.6M | 23.7M | 15.1M |
| Total Current Liabilities | 171.0M | 81.8M | 104.1M | 67.3M | 48.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 329.0M | 47.7M | 252.6M | 278.8M | 282.2M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 303.1M | 292.0M | 294.8M | 162.0M | 175.0M |
| Total Non-Current Liabilities | 672.2M | 390.8M | 617.2M | 478.5M | 482.2M |
| Total Liabilities | 843.2M | 472.7M | 721.4M | 545.8M | 530.5M |
| Equity | |||||
| Common Stock | 3.1M | 3.0M | 2.7M | 2.6M | 2.5M |
| Retained Earnings | -3.2B | -3.2B | -3.2B | -3.2B | -3.1B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -51.0M | -78.8M | -246.2M | -250.5M | -209.3M |
| Key Metrics | |||||
| Total Debt | 367.4M | 47.7M | 272.6M | 288.4M | 289.2M |
| Working Capital | 120.5M | 186.5M | 269.3M | 167.6M | 171.1M |
Balance Sheet Composition
MannKind Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 5.9M | 27.6M | -11.9M | -87.4M | -80.9M |
| Depreciation & Amortization | 12.3M | 9.0M | 5.8M | 6.3M | 3.2M |
| Stock-Based Compensation | 24.2M | 21.4M | 17.6M | 13.4M | 12.2M |
| Working Capital Changes | -39.1M | -27.2M | 17.4M | -7.8M | -21.3M |
| Operating Cash Flow | 8.1M | 34.4M | 31.2M | -63.4M | -78.4M |
| Investing Activities | |||||
| Capital Expenditures | -4.6M | -9.7M | -42.4M | -7.6M | -11.5M |
| Acquisitions | -347.7M | 0 | 0 | -15.3M | 0 |
| Investment Purchases | -157.8M | -280.8M | -79.1M | -79.5M | -199.1M |
| Investment Sales | 215.3M | 193.4M | 119.2M | 107.3M | 59.1M |
| Investing Cash Flow | -304.8M | -96.6M | -2.0M | 4.9M | -151.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 325.0M | - | 0 | 0 | 332.2M |
| Debt Repayment | 0 | -133.2M | -6.9M | -18.0K | -51.2M |
| Financing Cash Flow | 313.1M | -140.4M | 134.8M | 18.6M | 259.2M |
| Free Cash Flow | 13.7M | 32.8M | -8.3M | -88.3M | -73.2M |
| Net Change in Cash | 16.4M | -202.7M | 164.0M | -39.9M | 29.2M |
Cash Flow Trend
MannKind Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
135.00
Forward P/E
13.50
Price to Book
-16.35
Price to Sales
2.39
PEG Ratio
-0.51
Profitability Ratios
Profit Margin
1.68%
Operating Margin
-6.87%
Return on Equity
-11.49%
Return on Assets
4.91%
Financial Health
Current Ratio
1.70
Debt to Equity
-9.23
Beta
1.04
Per Share Data
EPS (TTM)
$0.02
Book Value per Share
$-0.17
Revenue per Share
$1.27
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MNKD | 836.8M | 135.00 | -16.35 | -11.49% | 1.68% | -9.23 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






